AstraZeneca Pharma India Ltd shares declined more than 4% in early trade on February 12 (IST) after the company reported its Q3 standalone results. The stock came under pressure despite a strong rise in revenue, as a sharp contraction in EBITDA and margins weighed on investor sentiment.
As of 9:23 AM (IST), the stock was trading lower compared to its previous close of ₹9,068.00. It opened at ₹8,790.00 and touched an intraday low of ₹8,618.00, while the day’s high stood at ₹8,790.00. The stock’s 52-week range is between ₹6,620.10 and ₹10,691.00.
Q3 Results Snapshot (Standalone, YoY)
For the third quarter, revenue rose 38.9% year-on-year to ₹612 crore compared to ₹440 crore in the same quarter last year, reflecting strong top-line growth.
However, EBITDA declined 41.8% to ₹44.8 crore versus ₹76.9 crore a year ago. The EBITDA margin contracted sharply by 1,020 basis points to 7.3%, down from 17.5% in the corresponding period last year.
Net profit showed modest growth, rising 5.6% to ₹32.6 crore compared to ₹30.9 crore in Q3 of the previous financial year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.